- Home
- ZTS vs BCTXZ Comparison
ZTS vs BCTXZ Comparison
Compare ZTS & BCTXZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTS
- BCTXZ
- Stock Information
- Founded
- ZTS 1952
- BCTXZ N/A
- Country
- ZTS United States
- BCTXZ Canada
- Employees
- ZTS N/A
- BCTXZ 12
- Industry
- ZTS Biotechnology: Pharmaceutical Preparations
- BCTXZ
- Sector
- ZTS Health Care
- BCTXZ
- Exchange
- ZTS Nasdaq
- BCTXZ Nasdaq
- Market Cap
- ZTS N/A
- BCTXZ N/A
- IPO Year
- ZTS 2013
- BCTXZ N/A
- Fundamental
- Price
- ZTS $154.92
- BCTXZ $1.00
- Analyst Decision
- ZTS Buy
- BCTXZ
- Analyst Count
- ZTS 8
- BCTXZ 0
- Target Price
- ZTS $212.13
- BCTXZ N/A
- AVG Volume (30 Days)
- ZTS 3.1M
- BCTXZ N/A
- Earning Date
- ZTS 05-06-2025
- BCTXZ N/A
- Dividend Yield
- ZTS 1.29%
- BCTXZ N/A
- EPS Growth
- ZTS 7.32
- BCTXZ N/A
- EPS
- ZTS 5.57
- BCTXZ N/A
- Revenue
- ZTS $9,286,000,000.00
- BCTXZ N/A
- Revenue This Year
- ZTS $2.67
- BCTXZ N/A
- Revenue Next Year
- ZTS $6.52
- BCTXZ N/A
- P/E Ratio
- ZTS $27.81
- BCTXZ N/A
- Revenue Growth
- ZTS 6.32
- BCTXZ N/A
- 52 Week Low
- ZTS $139.70
- BCTXZ N/A
- 52 Week High
- ZTS $200.33
- BCTXZ N/A
- Technical
- Relative Strength Index (RSI)
- ZTS 48.22
- BCTXZ N/A
- Support Level
- ZTS $148.99
- BCTXZ N/A
- Resistance Level
- ZTS $164.59
- BCTXZ N/A
- Average True Range (ATR)
- ZTS 4.55
- BCTXZ 0.00
- MACD
- ZTS 0.77
- BCTXZ 0.00
- Stochastic Oscillator
- ZTS 38.01
- BCTXZ 0.00
About BCTXZ BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.